Fosphenytoin
Fosphenytoin is a prodrug of Phenytoin (HY-B0448). Fosphenytoin can be converted to Phenytoin in vivo, which blocks voltage-gated sodium channels in a voltage- and use-dependent manner, prolonging inactivation and slowing recovery. Fosphenytoin enhances GABA responses and, at higher concentrations, mildly modulates calcium channels and increases sodium-potassium ATPase activity. Fosphenytoin raises the afterdischarge threshold, reduces the severity and duration of seizures, alleviates pain-like behavior, and protects hippocampal pyramidal neurons after ischemia without altering GFAP immunoreactivity. Fosphenytoin can be used in research on acute herpes zoster pain, epilepsy, and cerebral ischemia.
At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Fosphenytoin disodium) usually boasts enhanced water solubility and stability.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 93390-81-9
- Fòrmula: C16H15N2O6P
- Peso molecular:362.27
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Other In-stock Forms of Fosphenytoin
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Fosphenytoin (30 mg/kg; i.m.; single injection at 5 minutes after resuscitation) preserves hippocampal CA1 pyramidal neurons in rats after transient global ischemia[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (female, 6 weeks old at start, 18-20 g) bearing acute herpes zoster pain[2]
-
Dosage:15 mg/kg; 30 mg/kg
-
Administration:i.v.; single administration on day 6 after HSV-1 inoculation; before behavioral testing
-
Result:On day 6 after HSV-1 inoculation, 15 mg/kg i.v. suppressed 0.17-g mechanical allodynia at 3 h after administration; both 15 and 30 mg/kg inhibited 1.20-g mechanical hyperalgesia around 2-4 h after administration.
Table 1 reported mean differences from vehicle for the 0.17-g ipsilateral response of 0.180 (15 mg/kg) and 0.119 (30 mg/kg), and for the 1.20-g ipsilateral response of 0.405 (15 mg/kg) and 0.299 (30 mg/kg).
15 and 30 mg/kg reduced HSV-1-induced spontaneous licking in a dose-dependent manner; the 30 mg/kg dose produced the greatest numerical suppression among all trial drugs.
-
Animal Model:Wistar (female; Harlan-Winkelmann, Borchen, Germany)[4]
-
Dosage:6.25, 12.5, 25, and 50 mg/kg (Phenytoin equivalents); 10.5 mg/kg (6.25 mg/kg Phenytoin equivalent), 20.9 mg/kg (12.5 mg/kg Phenytoin equivalent), 83.5 mg/kg (50 mg/kg Phenytoin equivalent)
-
Administration:i.p.; single injection; 60 min before ADT determination
-
Result:Dose-dependently increased the ADT.
The 10.5 mg/kg dose (6.25 mg/kg phenytoin equivalent) was without effect on ADT, whereas 20.9 mg/kg (12.5 mg/kg phenytoin equivalent) increased ADT by almost 100%.
At the highest dose tested (83.5 mg/kg; 50 mg/kg phenytoin equivalent), seizure severity and seizure duration at threshold were reduced; the decrease in seizure severity was small, and generalized seizures were still seen in most rats at ADT current.
Afterdischarge duration was not changed.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 93390-81-9
-
Peso molecular 362.27
-
Fòrmula C16H15N2O6P
-
SMILES
O=C1N(COP(O)(O)=O)C(C(C2=CC=CC=C2)(C3=CC=CC=C3)N1)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Varia SA, et al. Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. J Pharm Sci. 1984;73(8):1068-1073. [Content Brief]
[2]. Takasaki I, et al. Fosphenytoin Alleviates Herpes Simplex Virus Infection-Induced Provoked and Spontaneous Pain-Like Behaviors in Mice. Biol Pharm Bull. 2022 Mar 1;45(3):360-363. [Content Brief]
[3]. Aleyadeh R, et al. Fosphenytoin. 2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. [Content Brief]
[4]. Löscher W, et al. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin. Epilepsy Res. 1998 Mar;30(1):69-76. [Content Brief]
[5]. Chan SA, et al. Fosphenytoin reduces hippocampal neuronal damage in rat following transient global ischemia. Acta Neurochir (Wien). 1998;140(2):175-80. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fosphenytoin Related Classifications
HY-B1657 Related Classifications
Powered by Bioz